Showing 7461-7470 of 8834 results for "".
- Soliton Seeks 510k Clearance for RAP Anti-Cellulite Devicehttps://practicaldermatology.com/news/soliton-seeks-510-clearance-for-rap-anti-cellulite-device/2460452/Soliton, Inc. filed for 510(k) premarket clearance with the U.S. Food and Drug Administration (FDA) of its second-generation Rapid Acoustic Pulse (RAP) device for the reduction in the appearance of cellulite. The RAP device was previously cleared by the FDA as an accessory to a 1064 nm
- ISD Survey: Climate Change Is A Real Threat to Skin Healthhttps://practicaldermatology.com/news/isd-survey-climate-change-is-a-real-threat-to-skin-health/2460451/The vast majority of dermatologists (95.6 percent) believe climate change is occurring and 88.6 percent indicated that climate change will impact the incidence of skin diseases in their areas, according to an online survey was conducted by the International Society of Dermatology's (ISD)
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Ortho Dermatologics Launches Arazlo Lotion in the UShttps://practicaldermatology.com/news/ortho-dermatologics-launches-arazlo-lotion-in-the-us/2460447/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics launched Arazlo (tazarotene) Lotion, 0.045%. Now available commercially to health care professionals in the US, it was FDA approved in December 2019 as the first tazaroten
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
- Cynosure Reopening Survey: If You Wear Masks, They Will Come Backhttps://practicaldermatology.com/news/cynosure-reopening-survey-if-you-wear-masks-they-will-come-back/2460441/Fully 85 percent of people plan to return to aesthetic treatments within 12 months of COVID-19 restrictions being lifted, and 63 percent plan to return to practices within just three months of restrictions being lifted in their respective countries, according to a
- Regenerative Medicine Business News: Bimini Acquires Healeonhttps://practicaldermatology.com/news/regenerative-medicine-business-news-bimini-acquires-healeon/2460432/Bimini Health Tech has acquired Healeon Medical, Inc., a company that designs, develops, manufactures, and markets medical devices for autologous, point-of-care treatments. Healeon's products include: the signature HD PRP system which fe
- Burt's Bees Natural Retinol Alternative Works Well in Sensitive Skinhttps://practicaldermatology.com/news/burts-bees-natural-retinol-alternative-works-well-in-sensitive-skin/2460430/Three new studies from Burt’s Bees highlight the safety and efficacy of Bakuchiol, a natural retinol alternative, as well as a new facial oil and lip balm. The findings were presented online at the American Academy of Dermatology (AAD
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap